ReviewThe British journal of dermatology2015
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.
Review in The British journal of dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 94 citations in OpenAlex.
- The immunology of vitiligo.Nature reviews. Immunology · 2026Review
- Comprehensive Overview of Cytokine Interplay in Vitiligo: A Decade of Meta-Analyses Systematically Reviewed.Life (Basel, Switzerland) · 2025Review
- Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity.The Journal of clinical investigation · 2025Review
- Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications.Journal of clinical medicine · 2024Review
- Tumor Necrosis Factor-Alpha: Ally and Enemy in Protean Cutaneous Sceneries.International journal of molecular sciences · 2024Review
- Vitiligo in a Patient Receiving Adalimumab for Idiopathic Uveitis.Turkish journal of ophthalmology · 2024Article
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?Frontiers in immunology · 2024Review
- Anti-tumor immunity and vitiligo: from immune-related adverse reactions to protection from cancer.Immunotherapy · 2024Article
- Exploring mechanisms of skin aging: insights for clinical treatment.Frontiers in immunology · 2024Review
- Advances in vitiligo: Update on therapeutic targets.Frontiers in immunology · 2022Review
- Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.International journal of molecular sciences · 2021Review
- A Case of New-Onset Vitiligo in a Healthy Volunteer After Administration of Adalimumab.Annals of dermatology · 2021Article
- Novel immunological and genetic factors associated with vitiligo: A review.Experimental and therapeutic medicine · 2021Review
- Vitiligo, From Physiopathology to Emerging Treatments: A Review.Dermatology and therapy · 2020Review
- Analysis of molecular and clinical parameters of 4-year adalimumab therapy in psoriatic patients.Postepy dermatologii i alergologii · 2020Article
- Deciphering skin re-pigmentation patterns in vitiligo: an update on the cellular and molecular events involved.Chinese medical journal · 2020Review
- Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis.Postepy dermatologii i alergologii · 2020Article
- Antigen Specificity Enhances Disease Control by Tregs in Vitiligo.Frontiers in immunology · 2020Article
- Autoimmunity in Segmental Vitiligo.Frontiers in immunology · 2020Review
- Therapeutic effects of iNOS inhibition against vitiligo in an animal model.European journal of translational myology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Tumour necrosis factor (TNF)-α, a proinflammatory cytokine central to many autoimmune diseases, has been implicated in the depigmentation process in vitiligo. We review its role in vitiligo by exploring its pro- and anti-inflammatory properties and examine the effects of blocking its actions with TNF-α antagonist therapeutics in reports available in the literature. We found that TNF-α inhibition halts disease progression in patients with progressive vitiligo but that, paradoxically, treatment can be associated with de novo vitiligo development in some patients when used for other autoimmune conditions, particularly when using adalimumab and infliximab. These studies reinforce the importance of stating appropriate outcomes measures, as most pilot trials propose to measure repigmentation, whereas halting depigmentation is commonly overlooked as a measure of success. We conclude that TNF-α inhibition has proven useful for patients with progressive vitiligo, where TNF-α inhibition is able to quash cytotoxic T-cell-mediated melanocyte destruction. However, a lingering concern for initiating de novo disease will likely prevent more widespread application of TNF inhibitors to treat vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.